Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 98, Issue -, Pages 806-812Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2018.01.002
Keywords
Hepatocellular carcinoma; Baicalein; Multidrug resistance; P-glycoprotein; Chemotherapy
Funding
- National Natural Science Foundation of China [81503310, 81603159]
- Program for Changjiang Scholars and Innovative Research Team in University [ITR1171]
- China Postdoctoral Science Foundation [2015M582679]
- Science Research Foundation of the Second Affiliated Hospital of Xi'an Jiaotong University [YJ(ZD) 201415]
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) has a dismal prognosis in part because of multi-drug resistance (MDR). Baicalein is a flavonoid extracted from Radix Scutellariae with anti-HCC activity. We tested the effects of Baicalein on multi-drug resistant HCC cells (Bel7402/5-FU) known to be resistant to the anticancer drugs 5-FU and Epirubicin. Flow cytometry analysis showed that treatment with 5 mu g/ml and 10 mu g/ml Baicalein resulted in increases in the intra-cellular concentrations of Rho123 and Epirubicin in the corresponding group of cells compared to untreated cells, illustrating that Baicalein reverses MDR in Bel7402/5-FU cells. Bel7402/5-FU cells displayed increased P-glycoprotein (P-gp)-mediated drug efflux. However, this efflux was inhibited in cells pre-incubated in Baicalein for 48 h. Moreover, Baicalein induced apoptosis and autophagy and decreased P-gp and Bcl-xl expression levels. All of these results indicate that Baicalein can reverse P-gp-mediated MDR in HCC and may thus be useful for the treatment of drug-resistant HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available